Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

Similar documents
1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.

Abstract Background: Methods: Results: Conclusions:

Impact of Lesion Length on Chronic Total Occlusion Intervention Outcomes

Seung-Woon Rha, MD, PhD FACC, FAHA, FESC, FSCAI, FAPSIC. Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea.

Acute Myocardial Infarction Patients

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Non-cardiac Procedures and

Prevention of Coronary Stent Thrombosis and Restenosis

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD

PROMUS Element Experience In AMC

The MAIN-COMPARE Study

LM stenting - Cypher

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Unprotected LM intervention

Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

The MAIN-COMPARE Registry

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

Medicine OBSERVATIONAL STUDY

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Experience of Korea Acute Myocardial Infarction Registry (KAMIR)

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea

PCI for Left Anterior Descending Artery Ostial Stenosis

Acute and Subacute Stent Thrombosis in a Patient With Clopidogrel Resistance: A Case Report

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

BMS vs. DES vs. CABG

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

Bern-Rotterdam Cohort Study

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

NCVD-PCI Registry. Percutaneous Coronary Intervention (PCI) Registry, MALAYSIA c/o National Heart Association of Malaysia

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Impact of Aortic Stiffness on Further Cardiovascular Events in Patients with Chest Pain : A Invasive Study

New Generation Drug- Eluting Stent in Korea

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

STEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital

Percutaneous Intervention of Unprotected Left Main Disease

Clopidogrel Date: 15 July 2008

Cover Page. The handle holds various files of this Leiden University dissertation

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

One-year clinical outcomes in invasive treatment strategies for acute ST-elevation myocardial infarction complicated by cardiogenic shock in elderly

Integrated Use of IVUS and FFR for LM Stenting

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry

Perspective of LM stenting with Current registry and Randomized Clinical Data

Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)

Research Article. Open Access

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

Updated and Guideline Based Treatment of Patients with STEMI

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Acute Coronary Syndromes

DECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.

Cindy L. Grines MD FACC FSCAI

Update on Antithrombotic Therapy in Acute Coronary Syndrome

PCI for Long Coronary Lesion

DIAMOND Study Investigators

2010, Metzler Helfried

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

Hyang Ki Min, Ji Young Park, Jae Woong Choi, Sung Kee Ryu, Seunghwan Kim, Chang Sup Song, Dong Shin Kim, Chi Woo Song, Se Jong Kim, Young Bin Kim

Drug Eluting Stents: Bifurcation and Left Main Approach

Count Down to COMBAT

Timing of Surgery After Percutaneous Coronary Intervention

COMBAT- Revised Protocol

Original Article. Introduction. Korean Circulation Journal

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine

INSIDE INFORMATION YOU CAN T IGNORE

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Hyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018

Continuing Medical Education Post-Test

Clinical Investigations

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

DECLARATION OF CONFLICT OF INTEREST

Rationale for Percutaneous Revascularization ESC 2011

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI

Approach to Multi Vessel disease with STEMI

Bifurcations Bad Krozingen I

Controversies in Cardiac Pharmacology

A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI

Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Non-LM bifurcation studies of importance in 2011

Transcription:

Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*, Sureshkumar Ramasamy, Kanhaiya L. Poddar, Ji Young Park, Kang-Yin Chen, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong* Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

Abstract Background: There are limited data regarding the prognosis of acute myocardial infarction (AMI) patients (pts) with Left main coronary artery (LMCA) disease as compared with those of pts with non left main disease patients. Methods: The study population consisted of 7038 consecutive acute AMI pts enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) study. We compared the clinical outcomes of AMI pts with LMCA disease (n=154, 2.18%) to those of pts with non- LMCA disease (n=6884, 97.82%) who underwent percutaneous coronary intervention (PCI) with DES. Results: The baseline clinical and procedural characteristics were balanced between pts with LMCA disease to those of pts with non- LMCA disease except higher number of elderly patients, prior ischemic heart disease pts, higher triple vessel disease, higher number of stents, larger diameter size stents, higher usage of unfractionated heparin, Glycoprotein IIb IIIa inhibitors, Cilostazol were noted in the left main group. In hospital mortality (p=015,0r 6.432) and developments of cardiogenic shock in the hospital were higher in the LMCA group on the multivariate analysis. At 8 months, the major clinical outcomes including Total major cardiovascular events (MACE), cumulative mortality, Any MI, and repeat Revascularization, were higher in LMCA group. (Table). Conclusion: The prevalence of LMCA disease was in less proportion (3.43%) in the AMI setting but showed worst eight month major clinical outcomes due to very high in hospital mortality, higher Total MACE, Cumulative mortality, Repeat revacularization and cumulative recurrent MI inspite of the drug eluting stents implantation.

Background 1. Patients (Pts) with acute myocardial infarction (AMI) caused by acute occlusion in left main coronary artery (LMCA) lesion is usually fatal and critical clinical setting in real world clinical practice. 2. However, there are limited data regarding the prognosis of AMI pts with LMCA disease as compared with those of pts with non left main disease patients.

Purpose To predict the midterm clinical outcomes after the percutaneous coronary interventions (PCI) with drug-eluting stent (DES) implantation in the Left main vs Non Left Main AMI Patients.

Methods 1. Study Population ; The study population consisted of 7038 consecutive AMI pts enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR). 2. Study groups ; We compared the clinical outcomes of AMI pts with LMCA disease (n=154 pts, 2.18%) to those of pts with non- LMCA disease (n=6884 pts, 97.82%) who underwent percutaneous coronary intervention (PCI) with DES.

Methods 3. Antiplatelet therapy 1) All pts received Aspirin; 100 mg orally, indefinitely 2) All pts received Clopidogrel (Plavix ) preloaded 300-600 mg before PCI, followed by daily administration of 75 mg and encouraged to continue at least for 1 year. 3) In case of suspicious higher risk of stent thrombosis; Routine triple antiplatelets (Aspirin, Clopidogrel and Cilostazol) for one month, then changed to dual antiplatelets

Methods 4. Antithrombotic therapy 1) Enoxaparin (Clexane ); 60mg bid before PCI and after PCI during the hospital stay (within 7 days). 2) Unfractionated Heparin; a bolus of 50 U/kg prior to PCI for 1 st one hour 3) GP IIbIIIa blocker (Reopro ); depend on physician s discretion

Methods 5. Percutaneous Coronary Intervention (PCI) Procedure 1) A variety of atheroablative devices were not utilized and mostly simple predilation or was performed to get an adequate luminal diameter which was necessary to accommodate the unexpanded DES or BMS and their delivery system. 2) Thrombus aspiration was done using Thrombuster II catheter or Export catheter if there were significant angiographic visible thrombi in the target lesion before stenting. 6. Study End Points ; Individual clinical hard endpoints and total major adverse cardiac events (MACE) at 12 months were evaluated.

Statistics 1. All statistical analyses were performed using SPSS 17.0. 2. Continuous variables were expressed as means ± standard deviation and were compared using Student s t-test. 3. Categorical data were expressed as percentages and were compared using chi-square statistics or Fisher s exact test. 4. Multivariate analysis was used to test the association of Total occlusion of IRA with 12 month MACE 5. A P-value of 0.05 was considered statistically significant.

Results

Results 1. Baseline Characteristics ; The baseline clinical and procedural characteristics were balanced between pts with LMCA disease to those of pts with non- LMCA disease except higher number of elderly patients, prior ischemic heart disease pts, higher triple vessel disease, higher number of stents, larger diameter size stents, higher usage of unfractionated heparin, Glycoprotein IIb IIIa inhibitors, Cilostazol were noted in the left main group.

Results 2. In-hospital Clinical Outcomes ; In hospital mortality (p=015,0r 6.432) and developments of cardiogenic shock in the hospital were higher in the LMCA group on the multivariate analysis. 3. Mid-term Clinical Outcomes ; At 8 months, the major clinical outcomes including total MACE, cumulative mortality, Any MI, and repeat revascularization (target lesion & vessel revascularization; TLR & TVR), were higher in LMCA group (Table).

Twelve-Month Clinical Outcomes (on Multivariate analysis) Variables, N (%) LMCA Group (n=154 pts) Non-LMCA Group (n=6884 pts) P value Total deaths 23 (14.9) 320 (4.6) 0.006* Cardiac Deaths 19 (12.3) 184 (2.7) 0.010* Any MI 11 (7.1) 115 (1.7) 0.033* Repeat Revascularization 12 (7.8) 292 (4.2) 0.023* TLR-PCI 4 (2.6) 72 ( 1.0) 0.164 TVR-PCI 8 (5.2) 116 (1.7) 0.081 CABG 3 (1.9) 30 (0.4) 0.124 Total MACE 40 (26.0) 741 (10.8) <0.001*

Conclusion The prevalence of LMCA disease was in less proportion (3.43%) in the AMI setting but showed worst cumulative eight-month major clinical outcomes due to very high in-hospital mortality, cumulative mortality, repeat revascularizations recurrent MI and higher total MACE in spite of the DES implantation.